A PYMNTS Company

US: Novartis to buy The Medicines Co.

By  |  November 24, 2019

Novartis is nearing a deal to buy cholesterol-drug maker The Medicines  for nearly US$7 billion, in an expensive bid to expand its reach in the lucrative market for heart treatments, reported the Wall Street Journal. 

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Using a fully diluted share count, the deal is worth about US$9.7 billion, one of the people said. 

    The acquisition would help Novartis, which has a market value of more than US$200 billion, bulk up in a corner of the health-care market it is already targeting with drugs including its heart-failure treatment Entresto.

    The cholesterol drug under development by Medicines, based in Parsippany, N.J., is aimed at patients who aren’t well-treated by older statin pills. 

    Pairing the Novartis and Medicines therapies would give sales representatives more products to peddle to heart doctors, potentially boosting sales of each.

    The Medicines drug is based on relatively new technology that uses the body’s molecular messengers, known as RNA, to turn off genes playing a role in a disease.The technology is known as RNA interference.

    Full Content: Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.